The use of parathyroid hormone in the treatment of osteoporosis.
about
Disorders of bone remodelingBreaking new ground to build boneBim, Bak, and Bax regulate osteoblast survival.A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats.Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.Romosozumab for the treatment of osteoporosis.Recombinant human parathyroid hormone related protein 1-34 and 1-84 and their roles in osteoporosis treatment.Validation of urinary calcium isotope excretion from bone for screening anabolic therapies for osteoporosis.Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectivesHypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone.Teriparatide - Indications beyond osteoporosis.Glucocorticoid-induced osteoporosis: treatment update and review.Effect of antiresorptive and anabolic bone therapy on development of osteoarthritis in a posttraumatic rat model of OATeriparatide in the treatment of recurrent fractures in a Rett patientEffects of a single injection of teriparatide on bone turnover markers in postmenopausal women.Male osteoporosis.Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using AllograftsManagement of osteoporosis among home health and long-term care patients with a prior fractureAngiotensin II type 2 receptor blockade increases bone mass.PTH promotes allograft integration in a calvarial bone defect.Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans.Sclerostin: therapeutic horizons based upon its actions.Osteodystrophy in chronic liver diseases.Parathyroid hormone induction of cyclooxygenase-2 in murine osteoblasts: role of the calcium-calcineurin-NFAT pathway.Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy.Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats.Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.In vitro refolding with simultaneous purification of recombinant human parathyroid hormone (rhPTH 1-34) from Escherichia coli directed by protein folding size exclusion chromatography (PF-SEC): implication of solution additives and their role on aggThe Inhibitory Effect of Angelica tenuissima Water Extract on Receptor Activator of Nuclear Factor-Kappa-B Ligand-Induced Osteoclast Differentiation and Bone Resorbing Activity of Mature Osteoclasts.Bone microarchitecture in Rett syndrome and treatment with teriparatide: a case report.Effects of strontium ranelate on osseointegration of titanium implant in osteoporotic rats.Osteoporosis in menProtective Effects of 2,3,5,4'-Tetrahydroxystilbene-2--β-d-glucoside on Ovariectomy Induced Osteoporosis Mouse ModelTeriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I
P2860
Q28295303-848EEA48-1DD3-4443-9787-8FE3FBACBE20Q30443900-3A6EDE6D-43AE-4C9D-A12C-CF616A8C3DB7Q33648236-5184EBE2-2C03-4407-A7DC-3DD705354A3DQ33779634-F336CCA1-6A15-4AAA-91F0-BE4613A58F2CQ33837249-DAB65627-C637-4E66-9B6B-28AE9C2B4563Q34107428-DAB7009E-86B1-41B0-B54B-C78686594D33Q34680463-F2CAEB0E-C0C5-415C-83FA-5E27AEC03B1BQ35091637-4B255810-94BD-4559-BD8B-D775D9FD3A7CQ35195886-C5645E43-8DA6-4FE5-9850-F55E5A991F0EQ35744492-5987D422-9DEC-429A-BFE3-1775AA9FB1A8Q35755184-396CDD0C-2E86-4D87-BDC5-6B4B151B0169Q35967736-2933DC04-4E3D-457D-BBF7-58E0EFDC21F0Q36059394-1E651A8F-35E3-468C-81C5-CB9DA69F2FE7Q36255352-943CCC85-A54E-453D-996D-2845B2B3A731Q36451744-AF2FBE87-7707-4F01-9EC4-6716A020D3FDQ36508350-A0DF61D3-6DA8-47A3-92AF-93168B6DA7CCQ36700839-F550C278-F5F7-42BD-88BB-7BF3DBE7534BQ36852779-DB35EAAC-7E19-4DA3-B5C3-FD399C8E7094Q37287270-BF4ADE30-9836-4849-9079-83922CEEA5F1Q37344123-B0F8BF2C-ECF1-44F0-9557-E8260F9BADE0Q37515793-C2FA221E-A764-4402-ABA9-255B966B90A2Q37956373-9EA9508D-9663-4050-9FA7-A49A669C30A2Q37974871-2FC939ED-A39C-4452-865F-AA361BF0EC9FQ37975457-77CE032F-8809-49FE-9A8C-8B3ED96CE72BQ38349696-AEC51445-2858-426F-A68E-67A83BE6B743Q39889561-5B431A3F-20CD-4844-B3D2-2C20EDE92901Q42660768-8B64BB97-D7CD-47AD-BBA6-FEF47602F9E9Q43974287-28D7492A-3938-45C2-8F91-D22FC42205B4Q44533571-1CFDC7AC-9C62-4014-B018-87F1D7AD6E24Q46583319-38496D5A-533F-4679-8158-8CAA495A32FDQ47353779-35E07DCE-8964-407C-A708-D5C70ED120A4Q48079300-1DF701C1-6413-4ABD-BE4E-04ACDA76C5ACQ50521177-9A254784-FF76-4637-80BE-5944AB5B52C5Q51383833-178E5523-E804-44D9-9FD7-F7B1FE66112DQ56110001-662E1ABE-E5B5-4A6C-8317-6DF97C2803E4Q58697346-046A40F7-A9C3-4CD8-8DCB-3C4B6CF2B9D8Q58903531-DF803129-5F36-4826-9F57-4631194832A6
P2860
The use of parathyroid hormone in the treatment of osteoporosis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The use of parathyroid hormone in the treatment of osteoporosis.
@ast
The use of parathyroid hormone in the treatment of osteoporosis.
@en
type
label
The use of parathyroid hormone in the treatment of osteoporosis.
@ast
The use of parathyroid hormone in the treatment of osteoporosis.
@en
prefLabel
The use of parathyroid hormone in the treatment of osteoporosis.
@ast
The use of parathyroid hormone in the treatment of osteoporosis.
@en
P1476
The use of parathyroid hormone in the treatment of osteoporosis.
@en
P2093
Mishaela R Rubin
Monica Girotra
P2888
P304
P356
10.1007/S11154-006-9007-Z
P577
2006-06-01T00:00:00Z